{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017582","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.161561+00:00","generated_at":"2026-06-21T20:57:45.769684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25","bullets":["Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.","Cash and investments $142.6M as of Sep 30, 2022, down from $167.4M at Dec 31, 2021; runway into 2H25.","IMPAHCT Phase 2b/3 trial enrollment delayed; topline data expected Q4 2023 or Q1 2024.","Expanded IP with two new U.S. patents (11,413,289 and 11,464,776) issued; notice of allowance for another.","Sanjeev Khindri joined as SVP Clinical Development; brings respiratory and PAH experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017582","json":"https://secwatch.observer/filing/0001558370-22-017582.json","markdown":"https://secwatch.observer/filing/0001558370-22-017582.md","text":"https://secwatch.observer/filing/0001558370-22-017582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/0001558370-22-017582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/tmb-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:57:45.769684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7808d2a78ae4ed3cd01d7b825fdbce387cd6a807","claim":"Jade Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $13.6 million.","evidence_excerpt":"On November 14, 2022, Aerovate Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/0001558370-22-017582-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$13.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}